APOA1 and myeloid sarcoma: These findings have provided evidence that higher level of ApoA1 is significantly correlated with better cerebral perfusion in MS patients and less gray matter and cortical atrophy after adjusting for the baseline serum neurofilament (sNfL) level as a marker of neurodegeneration [69,70,71].